ONA Therapeutics appoints Dr Michel Detheux as independent chair to board of directors
ONA Therapeutics, based in the Barcelona Science Park and focused on the discovery and development of therapeutic biologics targeting lipid metabolism to treat advanced cancer, today announces the appointment of Dr Michel Detheux as independent chair to its board of directors.
Dr Michel Detheux is a veteran biotech executive with 25 years’ experience within the industry. He is currently the president and CEO of iTeos Therapeutics (NASDAQ:ITOS), a clinical stage, publicly-traded biotech company developing novel immuno-oncology therapies focused on key mechanisms of immunosuppression. He has spearheaded several capital raises and transactions for iTeos, including an initial public offering on Nasdaq and strategic collaborations with Pfizer and GlaxoSmithKline.
Dr Detheux studied at the Université Catholique de Louvain, receiving his undergraduate degree and his PhD in biochemistry, before completing his post-doc at the University of Glasgow. He also holds a business certificate from Solvay Business School.
Valerie Vanhooren, chief cxecutive officer and co-founder of ONA Therapeutics says: “We are thrilled to welcome Dr Michel Detheux as Independent Chair to the Board of Directors. Dr Detheux’s expertise and outstanding track record will be invaluable to ONA as we advance our preclinical pipeline of novel therapies addressing the unmet medical need of patients with advanced cancer.”
Dr Michel Detheux, chair of ONA Therapeutics, says: “I am delighted to be joining ONA Therapeutics at this stage of the company’s growth and progression. ONA has a unique combination of novel science, good investor base and bright talents to develop highly innovative therapeutics.”
» For further information: ONA Therapeutics [+]